Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Neurocrine Biosciences Inc(NBIX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NBIX
09/25/2026: NBIX (1-star) is currently NOT-A-BUY. Pass it for now.
Neurocrine Biosciences is a specialized biopharmaceutical company that has become a key player in the neuroscience space, primarily through the success of its treatment for movement disorders, Ingrezza. The company has a stable, high-margin revenue base and a promising late-stage pipeline that offers significant growth potential. However, the business faces risks related to product concentration and the inherent unpredictability of clinical trials and regulatory approvals. Neurocrine may suit growth-oriented investors looking for exposure to specialized medicine, though they must monitor pipeline developments closely. While the company holds a strong position, investors should be aware that valuation and competitive pressures remain constant factors in the biotechnology industry.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers significant top-line expansion potential through pipeline advancement and indication growth. |
| Momentum investor | Strong fit while signal remains positive | Market adoption of core products and positive clinical data flow often drive favorable stock price momentum. |
| Value investor | Mixed fit | Biotech valuation is often driven by future pipeline success rather than current earnings multiples. |
| Dividend investor | Weak fit | Neurocrine does not pay a dividend as it prioritizes reinvestment for growth. |
| Low-risk investor | Weak fit | The company is subject to the inherent clinical, regulatory, and market risks typical of the biotechnology sector. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical trial outcomes and regulatory news cycles. |
| Valuation risk | Medium | Market expectations for future pipeline successes can lead to premium valuations that adjust quickly on negative news. |
| Competition risk (Neurology/Endocrine space) | Medium / high | Established competitors with deep pockets can challenge market share through pricing or superior clinical data. |
| Business quality | Medium | While the commercial business is strong, long-term stability depends on maintaining an active R&D pipeline. |
| Dividend income | Low / none | There is no income generation for investors seeking dividends. |
| Execution risk | Medium | Successful commercialization of new products and meeting clinical trial endpoints are critical for future performance. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -9.92% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.07B USD | Price to earnings Ratio 20.23 | 1Y Target Price 208.4 |
Price to earnings Ratio 20.23 | 1Y Target Price 208.4 | ||
Volume (30-day avg) 1.2M shares | Beta 0.38 | 52 Weeks Range 122.14 - 186.12 | Updated Date 09/27/2026 |
52 Weeks Range 122.14 - 186.12 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.84 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercialized Neurology Products | Revenue primarily from Ingrezza (valbenazine) sales in the U.S. | The company's primary source of cash is the sales of its leading drug for movement disorders. |
| Endocrine/Other Portfolio | Collaborations and sales of therapies for endometriosis and uterine fibroids. | Secondary revenue streams come from products targeting endocrine health, often managed via partnerships. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 20.23 | Forward PE 14.12 | Enterprise Value 14.42B | Price to Sales(TTM) 4.17 |
Enterprise Value 14.42B | Price to Sales(TTM) 4.17 | ||
Enterprise Value to Revenue 4.28 | Enterprise Value to EBITDA 15.65 | Shares Outstanding 101.65M | Shares Floating 100.37M |
Shares Outstanding 101.65M | Shares Floating 100.37M | ||
Percent Insiders 1.06 | Percent Institutions 102.75 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Neurocrine Biosciences Inc
Exchange NASDAQ | Headquarters San Diego, CA, United States | ||
IPO Launch date 1996-05-23 | President, CEO & Director Mr. Kyle W. Gano Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2500 | Website https://www.neurocrine.com |
Full time employees 2500 | Website https://www.neurocrine.com | ||
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.